Viking Therapeutics Stock Analysis

VKTX Stock  USD 32.65  0.09  0.28%   
Viking Therapeutics is undervalued with Real Value of 51.66 and Target Price of 110.0. The main objective of Viking Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Viking Therapeutics is worth, separate from its market price. There are two main types of Viking Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Viking Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Viking Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Viking Stock trading window is adjusted to America/New York timezone.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Viking Stock Analysis Notes

About 76.0% of the company outstanding shares are owned by institutional investors. The book value of Viking Therapeutics was at this time reported as 8.18. The company recorded a loss per share of 0.94. Viking Therapeutics had not issued any dividends in recent years. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company was incorporated in 2012 and is headquartered in San Diego, California. Viking Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. For more information please call Brian Lian at 858 704 4660 or visit https://www.vikingtherapeutics.com.

Viking Therapeutics Investment Alerts

Viking Therapeutics generated a negative expected return over the last 90 days
Viking Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (85.89 M) with profit before overhead, payroll, taxes, and interest of 0.
Viking Therapeutics currently holds about 155.02 M in cash with (73.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02.
Viking Therapeutics has a frail financial position based on the latest SEC disclosures
Over 76.0% of the company outstanding shares are owned by institutional investors
Latest headline from finance.yahoo.com: Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims Hers Health Dropped Today

Viking Therapeutics Upcoming and Recent Events

Earnings reports are used by Viking Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
14th of February 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Viking Largest EPS Surprises

Earnings surprises can significantly impact Viking Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-04-27
2022-03-31-0.19-0.21-0.0210 
2021-04-28
2021-03-31-0.17-0.19-0.0211 
2020-10-28
2020-09-30-0.15-0.130.0213 
View All Earnings Estimates

Viking Therapeutics Environmental, Social, and Governance (ESG) Scores

Viking Therapeutics' ESG score is a quantitative measure that evaluates Viking Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Viking Therapeutics' operations that may have significant financial implications and affect Viking Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Viking Therapeutics Thematic Classifications

In addition to having Viking Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Viking Stock Institutional Investors

Shares
Braidwell Lp2024-09-30
1.2 M
Susquehanna International Group, Llp2024-09-30
1.1 M
Alliancebernstein L.p.2024-09-30
M
International Assets Investment Management, Llc2024-09-30
M
Westfield Capital Management Company, L.p.2024-09-30
930.4 K
Amvescap Plc.2024-09-30
876.2 K
Hood River Capital Management Llc2024-09-30
815.7 K
Clearbridge Advisors, Llc2024-09-30
738.6 K
Viking Global Investors Lp2024-09-30
721.9 K
Fmr Inc2024-09-30
16.6 M
Vanguard Group Inc2024-09-30
10.2 M
Note, although Viking Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Viking Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.64 B.

Viking Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed(0.26)(0.27)
Return On Assets(0.21)(0.22)
Return On Equity(0.28)(0.30)

Management Efficiency

Viking Therapeutics has return on total asset (ROA) of (0.1268) % which means that it has lost $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.155) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.22 in 2025. Return On Capital Employed is likely to drop to -0.27 in 2025. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 443.4 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 755.8 K in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 3.32  3.49 
Tangible Book Value Per Share 3.32  3.49 
Enterprise Value Over EBITDA(15.19)(14.43)
Price Book Value Ratio 4.54  4.76 
Enterprise Value Multiple(15.19)(14.43)
Price Fair Value 4.54  4.76 
Enterprise Value342 M174.7 M
Understanding the operational decisions made by Viking Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta
0.994
Return On Assets
(0.13)
Return On Equity
(0.15)

Technical Drivers

As of the 18th of January 2025, Viking Therapeutics has the Variance of 26.77, risk adjusted performance of (0.14), and Coefficient Of Variation of (560.49). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viking Therapeutics, as well as the relationship between them.

Viking Therapeutics Price Movement Analysis

Study
Time Period
Deviations up
Deviations down
MA Type
Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Viking Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Viking Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Viking Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viking Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viking Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viking Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Brian Lian over three months ago
Disposition of 35000 shares by Brian Lian of Viking Therapeutics at 23.95 subject to Rule 16b-3
 
Brian Lian over three months ago
Disposition of 1000 shares by Brian Lian of Viking Therapeutics at 69.9 subject to Rule 16b-3
 
Singleton J Matthew over three months ago
Disposition of 20786 shares by Singleton J Matthew of Viking Therapeutics at 8.0 subject to Rule 16b-3
 
Mancini Marianna over six months ago
Disposition of 23746 shares by Mancini Marianna of Viking Therapeutics at 76.4045 subject to Rule 16b-3
 
Greg Zante over six months ago
Acquisition by Greg Zante of 28334 shares of Viking Therapeutics subject to Rule 16b-3
 
Greg Zante over six months ago
Disposition of 16610 shares by Greg Zante of Viking Therapeutics at 83.34 subject to Rule 16b-3
 
Brian Lian over six months ago
Disposition of 140000 shares by Brian Lian of Viking Therapeutics at 4.65 subject to Rule 16b-3
 
Greg Zante over six months ago
Acquisition by Greg Zante of 14553 shares of Viking Therapeutics at 5.8 subject to Rule 16b-3
 
Rouan Sarah Kathryn over a year ago
Acquisition by Rouan Sarah Kathryn of 32000 shares of Viking Therapeutics subject to Rule 16b-3
 
Greg Zante over a year ago
Sale by Greg Zante of 131029 shares of Viking Therapeutics
 
Greg Zante over a year ago
Exercise or conversion by Greg Zante of 37447 shares of Viking Therapeutics subject to Rule 16b-3
 
Charles Rowland over a year ago
Exercise or conversion by Charles Rowland of 40000 shares of Viking Therapeutics subject to Rule 16b-3

Viking Therapeutics Outstanding Bonds

Viking Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Viking Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Viking bonds can be classified according to their maturity, which is the date when Viking Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Viking Therapeutics Predictive Daily Indicators

Viking Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Viking Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Viking Therapeutics Corporate Filings

F4
6th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
F4
8th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
4th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
28th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
25th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
23rd of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Viking Therapeutics Forecast Models

Viking Therapeutics' time-series forecasting models are one of many Viking Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Viking Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Viking Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Viking Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Viking shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Viking Therapeutics. By using and applying Viking Stock analysis, traders can create a robust methodology for identifying Viking entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Viking Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Viking analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Viking analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
110.0Strong Buy15Odds
Viking Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Viking analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Viking stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Viking Therapeutics, talking to its executives and customers, or listening to Viking conference calls.
Viking Analyst Advice Details

Viking Stock Analysis Indicators

Viking Therapeutics stock analysis indicators help investors evaluate how Viking Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Viking Therapeutics shares will generate the highest return on investment. By understating and applying Viking Therapeutics stock analysis, traders can identify Viking Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow36.6 M
Common Stock Shares Outstanding94.3 M
Total Stockholder Equity348.4 M
Property Plant And Equipment Net1.1 M
Cash And Short Term Investments362.1 M
Cash55.5 M
Accounts Payable7.5 M
Net Debt-54.3 M
50 Day M A48.6158
Total Current Liabilities19.1 M
Other Operating Expenses100.8 M
Non Current Assets Total1.3 M
Non Currrent Assets Other139 K
Stock Based Compensation16.8 M

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.